NCT04092751View on ClinicalTrials.gov

Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

December 20, 2019

Study Completion Date

December 20, 2019

Conditions

Pharmacokinetics

Interventions

DRUG

PRA

Single oral 20-mg dose of PRA on Day 1 AM

DRUG

SCY-078 plus PRA

Twice daily (BID), every 12 hours (Q12H) oral doses of SCY-078 750 mg on Day 1 and Day 2; and on Day 3 a single AM dose of oral SCY 078 750 mg followed by a single 20-mg dose of PRA administered one hour later

Trial Locations (1)

2031

Scientia Clinical Research Limited Bright Building, Randwick